Research progress in DZNep in tumor therapy / 肿瘤

ABSTRACT

Enhancer of zeste homolog 2 (EZH 2) is considered to be a novel oncogene in recent years. 3-Deazaneplanocin A (DZNep, an inhibitor of EZH2), has been intensively focused for its effect upon cancers by exerting potential anti-proliferative and pro-apoptotic effects via blocking the EZH2 pathway. As a new chromatin modification drug, growing evidence suggests that DZNep is involved in pathophysiological process of tumor cells, such as proliferation, apoptosis, invasion, metastasis and vascularization. DZNep may provide a new approach for the treatment of tumors. This review summarizes the research progress in DZNep in tumor therapy.